Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena
Heavy Menstrual Bleeding, Abnormal Bleeding
About this trial
This is an interventional treatment trial for Heavy Menstrual Bleeding focused on measuring Heavy Menstrual Bleeding, Levonorgestrel relesing intrauterine system
Eligibility Criteria
Inclusion Criteria:
Women with complaints of abnormal bleeding during use of Mirena independently of the length of use
Exclusion Criteria:
Delivery in the last six months Breastfeeding Hematological disorder Use of anticoagulants Uterine leiomioma
Sites / Locations
- University of CampinasRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Ulipristal acetate 5mg/day/five days
Placebo 1 pill/day/five days
Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Ulipristal acetate at 5mg/day/five days Ulipristal 5mg daily for 5 days at the bleeding episode
Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Placebo at 1pill/day/five days Placebo one pill a day for 5 days at the bleeding episode